Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Lori Goldstein

Email
Center AffiliationsMolecular Therapeutics

Publications (101) (print view)

paginate
Blackwell KL, Zaman K, Qin S, Tkaczuk KH, Campone M, Hunt D, Bryce R, Goldstein LJ, Study G. Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clin Breast Cancer. 2019 Apr;19(2):97-104 e4.
Bleicher RJ, Chang C, Wang CE, Goldstein LJ, Kaufmann CS, Moran MS, Pollitt KA, Suss NR, Winchester DP, Tafra L, Yao K. Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Res Treat. 2019 Feb;173(3):603-17.
Goetz MP, Gradishar WJ, Anderson BO, Abraham J, Aft R, Allison KH, Blair SL, Burstein HJ, Dang C, Elias AD, Farrar WB, Giordano SH, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, Moran MS, Mortimer J, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Telli ML, Ward JH, Young JS, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 Feb;17(2):118-26.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. Journal of the National Cancer Institute. 2019 Feb;111(2):210-3.   PMCID: PMC6657277
Alberro JA, Ballester B, Deulofeu P, Fabregas R, Fraile M, Gubern JM, Janer J, Moral A, de Pablo JL, Penalva G, Puig P, Ramos M, Rojo R, Santesteban P, Serra C, Sola M, Solarnau L, Solsona J, Veloso E, Vidal S, Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Ohashi Y, Sakai K, Sugimachi K, Toi M, Tominaga T, Uchino J, Yoshida M, Coles CE, Haybittle JL, Mobus V, Leonard CF, Calais G, Garaud P, Collett V, Davies C, Delmestri A, Sayer J, Harvey VJ, Holdaway IM, Kay RG, Mason BH, Forbe JF, Franci PA, Wilcken N, Balic M, Bartsch R, Fesl C, Fitzal F, Fohler H, Gnant M, Greil R, Jakesz R, Marth C, Mlineritsch B, Pfeiler G, Singer CF, Steger GG, Stoger H, Canney P, Yosef HM, Focan C, Peek U, Oates GD, Powell J, Durand M, Mauriac L, Di Leo A, Dolci S, Larsimont D, Nogaret JM, Philippson C, Piccart MJ, Masood MB, Parker D, Price JJ, Lindsay MA, Mackey J, Martin M, Hupperets P, Bates T, Blamey RW, Chetty U, Ellis IO, Mallon E, Morgan DA, Patnick J, Pinder S, Lohrisch C, Nichol A, Bartlett JM, Bramwell VH, Chen BE, Chia SK, Gelmon K, Goss PE, Levine MN, Parulekar W, Pater JL, Pritchard KI, Shepherd LE, Tu D, Whelan T, Berry D, Broadwater G, Cirrincione C, Muss H, Norton L, Weiss RB, Abu-Zahara HT, Karpov A, Portnoj SL, Bowden S, Brookes C, Dunn J, Fernando I, Lee M, Poole C, Rea D, Spooner D, Barrett-Lee PJ, Manse RE, Monypenny IJ, Gordon NH, Davis HL, Cuzick J, Sestak I, Lehingue Y, Romestaing P, Dubois JB, Delozier T, Griffon B, Lesec'H JM, Mustacchi G, Petruzelka L, Pribylova O, Owen JR, Meier P, Shan Y, Shao YF, Wang X, Zhao DB, Howell A, Swindell R, Albano J, de Oliveira CF, Gervasio H, Gordilho J, Ejlertsen B, Jensen MB, Mouridsen H, Gelman RS, Harris JR, Hayes D, Henderson C, Shapiro CL, Christiansen P, Ejlertsen B, Ewertz M, Jensen MB, Mouridsen HT, Fehm T, Trampisch HJ, Dalesio O, de Vries EG, Rodenhuis S, van Tinteren H, Comis RL, Davidson NE, Gray R, Robert N, Sledge G, Solin LJ, Sparano JA, Tormey DC, Wood W, Cameron D, Chetty U, Dixon JM, Forrest P, Jack W, Kunkler I, Rossbach J, Klijn JG, Treurniet-Donker AD, van Putten WL, Rotmensz N, Veronesi U, Viale G, Bartelink H, Bijker N, Bogaerts J, Cardoso F, Cufer T, Julien JP, Poortmans PM, Rutgers E, van de Velde CJ, Cunningham MP, Huovinen R, Joensuu H, Costa A, Bonadonna G, Gianni L, Valagussa P, Goldstein LJ, Bonneterre J, Fargeot P, Fumoleau P, Kerbrat P, Lupors E, Namer M, Carrasco E, Martin M, Segui MA, Eierman W, Hilfrich J, Jonat W, Kaufmann M, Kreienberg R, Schumacher M, Bastert G, Rauschecker H, Sauer R, Sauerbrei W, Schauer A, Schumacher M, Blohmer JU, Costa SD, Eidtmann H, Gerber B, Jackisch C, Loib S, von Minckwitz G, de Schryver A, Vakaet L, Belfiglio M, Nicolucci A, Pellegrini F, Pirozzoli MC, Sacco M, Valentini M, McArdle CS, Smith DC, Stallard S, Dent DM, Gudgeon CA, Hacking A, Murray E, Panieri E, Werner ID, De Salvo GL, Del Bianco P, Zavagno G, Leone B, Vallejo CT, Zwenger A, Galligioni E, Lopez M, Erazo A, Medina JY, Horiguchi J, Takei H, Fentiman IS, Hayward JL, Rubens RD, Skilton D, Scheurlen H, Kaufmann M, Sohn HC, Untch M, Dafni U, Markopoulos C, Bamia C, Fountzilas G, Koliou GA, Manousou K, Mavroudis D, Klefstrom P, Blomqvist C, Saarto T, Gallen M, Canavese G, Tinterri C, Margreiter R, de Lafontan B, Mihura J, Roche H, Asselain B, Salmon RJ, Vilcoq JR, Brain E, de La Lande B, Mouret-Fourme E, Andre F, Arriagada R, Delaloge S, Hill C, Koscienly S, Michiels S, Rubino C, A'Hern R, Bliss J, Ellis P, Kilburn L, Yarnold JR, Martin M, Benraadt J, Kooi M, van de Velde AO, van Dongen JA, Vermorken JB, Castiglione M, Coates A, Colleoni M, Collins J, Forbes J, Gelbe RD, Goldhirsch A, Lindtner J, Price KN, Regan MM, Rudenstam CM, Senn HJ, Thuerlimann B, Bliss JM, Chilvers CE, Coombes RC, Hall E, Marty M, Buyse M, Possinger K, Schmid P, Untch M, Wallwiener D, Foster L, George WD, Stewart HJ, Stroner P, Borovik R, Hayat H, Inbar MJ, Peretz T, Robinson E, Camerini T, Formelli F, Martelli G, Di Mauro MG, Valagussa P, Perrone F, Amadori D, Martoni A, Pannuti F, Camisa R, Musolino A, Passalacqua R, Iwata H, Shien T, Abe O, Ikeda T, Inokuchi K, Kikuchi K, Sawa K, Sonoo H, Sadoon M, Tulusan AH, Kohno N, Miyashita M, Takao S, Ahn JH, Jung KH, Korzeniowski S, Skolyszewski J, Ogawa M, Yamashita J, Bastiaannet E, Liefers GJ, van de Velde CJ, Christiaens R, Neven P, Paridaens R, Van den Bogaert W, Gazet JC, Corcoran N, Deshpande N, di Martino L, Douglas P, Hacking A, Host H, Lindtner A, Notter G, Bryant AJ, Ewing GH, Firth LA, Krushen-Kosloski JL, Nissen-Meyer R, Anderson H, Killander F, Malmstrom P, Ryden L, Arnesson LG, Carstense J, Dufmats M, Fohlin H, Nordenskjold B, Soderberg M, Sundqvist M, Carpenter TJ, Murray N, Royle GT, Simmonds PD, Albain K, Barlow W, Crowley J, Hayes D, Gralow J, Hortobagyi G, Livingston R, Martino S, Osborne CK, Ravdin PM, Bergh J, Bondesso T, Celebiogl F, Dahlberg K, Fornander T, Fredriksson I, Frisell J, Goransson E, Iiristo M, Johansson U, Lenner E, Lofgren L, Nikolaidis P, Perbeck L, Rotstein S, Sandelin K, Skoog L, Svane G, af Trampe E, Wadstrom C, Janni W, Castiglione M, Goldhirsch A, Maibach R, Senn HJ, Thurlimann B, Bartlett JM, Bastiaannet E, Hadji P, Hozumi J, Rea D, van de Velde CJ, Holli K, Rouhento K, Safra T, Brenner H, Hercbergs A, Yoshimoto M, Paterson AH, Pritchard KI, Fyles A, Meakin JW, Panzarella T, Pritchard KI, Bahi J, Delaloge S, Lemonnier J, Martin AL, Reid M, Spittle M, Bishop H, Bundred NJ, Cuzick J, Ellis IO, Fentiman IS, Forbes JF, Forsyth S, George WS, Pinder SE, Sestak I, Deutsch GP, Gray R, Kwong DL, Pai VR, Peto R, Senanayake F, Boccardo F, Rubagotti A, Baum M, Forsyth S, Hackshaw A, Houghton J, Ledermann J, Monson K, Tobias JS, Carlomagno C, De Laurentiis M, De Placido S, Schem C, Williams L, Bell R, Cameron D, Coleman RE, Dodwell D, Hinsley S, Marshall HC, Hayes D, Pierce LJ, Basso SM, Lumachi F, Solomayer E, Coleman RE, Horsman JM, Lester J, Winter MC, Buzdar AU, Hsu L, Love RR, Ahlgren J, Garmo H, Holmberg L, Lindman H, Warnberg F, Asmar L, Jones SE, Aft R, Gluz O, Harbeck N, Liedtke C, Nitz U, Litton A, Wallgren A, Karlsson P, Linderholm BK, Chlebowski RT, Caffier H, Brufsky AM, Coleman RE, Llombart HA, Ebctcg, Ebctcg, Grocta Trialists. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncology. 2018 Jan;19(1):27-39.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Marcom PK, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli ML, Ward JH, Kumar R, Shead DA. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar;16(3):310-20.
Kornblum N, Zhao F, Manola J, Klein P, Ramaswamy B, Brufsky A, Stella PJ, Burnette B, Telli M, Makower DF, Cheema P, Truica CI, Wolff AC, Soori GS, Haley B, Wassenaar TR, Goldstein LJ, Miller KD, Sparano JA. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018 Jun;36(16):1556-63.
Martin JM, Goldstein LJ. Profile of abemaciclib and its potential in the treatment of breast cancer. Onco Targets Ther. 2018 Aug;11:5253-9.   PMCID: PMC6120573
Miller KD, O'Neill A, Gradishar W, Hobday TJ, Goldstein LJ, Mayer IA, Bloom S, Brufsky AM, Tevaarwerk AJ, Sparano JA, Le-Lindqwister NA, Hendricks CB, Northfelt DW, Dang CT, Sledge GW. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). J Clin Oncol. 2018 Sep;36(25):2621-9.   PMCID: PMC6118403
Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res Treat. 2017 Sep;165(2):375-82.   PMCID: PMC5682621
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz MP, Goldstein LJ, Isakoff SJ, Lyons J, Kelly Marcom P, Mayer IA, McCormick B, Moran MS, O'Regan RM, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Sitapati A, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 Apr;15(4):433-51.
Schott AF, Goldstein L, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez R, Kato G, Wicha MS. Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC). Clin Cancer Res. 2017 May 24;23(18):5358-65.   PMCID: PMC5600824
Sparano JA, Gray R, Oktay MH, Entenberg D, Rohan T, Xue X, Donovan M, Peterson M, Shuber A, Hamilton DA, D'Alfonso T, Goldstein LJ, Gertler F, Davidson NE, Condeelis J, Jones J. A metastasis biomarker (MetaSite Breast Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. NPJ breast cancer. 2017 Nov;3:42.   PMCID: PMC5678158
Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ. Erratum to: Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016 Dec;160(3):573.
Churilla TM, Egleston BL, Murphy CT, Sigurdson ER, Hayes SB, Goldstein LJ, Bleicher RJ. Patterns of multidisciplinary care in the management of non-metastatic invasive breast cancer in the United States Medicare patient. Breast Cancer Res Treat. 2016 Nov;160(1):153-62.   PMCID: PMC5064835
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Kelly Marcom P, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive breast cancer version 1.2016. JNCCN Journal of the National Comprehensive Cancer Network. 2016 Mar;14(3):324-54.
Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS. Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). Oncoimmunology. 2015 Sep;4(9):e985930.   PMCID: PMC4570112
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Breast cancer version 2.2015: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2015 Jan;13(4):448-75.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec;13(12):1475-85.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbe JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS, Poems S Investigators. Goserelin for Ovarian Protection During Breast-Cancer Adjuvant Chemotherapy. Obstetrical & Gynecological Survey. 2015 Jun;70(6):392-3.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. The New England journal of medicine. 2015 Mar 05;372(10):923-32.   PMCID: 4405231
Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast J. 2015 Mar;21(2):121-6.
Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P. Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type. Breast Journal. 2015 Jan;21(2):121-6.
Shih J, Bashir B, Gustafson KS, Andrake M, Dunbrack RL, Goldstein LJ, Boumber Y. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary. J Natl Compr Canc Netw. 2015 Aug;13(8):947-52.   PMCID: 4763101
Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, Carlson RW, Chang PJ, Sparano JA, Head B, Goldstein LJ, Haley B, Dakhil SR, Reid JE, Hartman AR, Manola J, Ford JM. Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. J Clin Oncol. 2015 Apr 06;33(17):1895-901.   PMCID: 4451172
Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience. J Clin Oncol. 2015 Feb;33(4):340-8.   PMCID: Pmc4302215
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 2014 Sep;32(27):2959-66.   PMCID: 4162494
Cole M, Parajuli S, Laske D, Goldstein L, Morrison T, Mukherjee A, Tumelty K, Tetzlaff E, von Mehren M, Inniss S. Peripheral primitive neuroectodermal tumor of the dura in a 51-year-old woman following intensive treatment for breast cancer. Am J Case Rep. 2014 Jan;15:294-9.   PMCID: Pmc4102603
Freedman GM, Fowble BL, Li T, Hwang ES, Schechter N, Devarajan K, Anderson PR, Sigurdson ER, Goldstein LJ, Bleicher RJ. Risk of positive nonsentinel nodes in women with 1-2 positive sentinel nodes related to age and molecular subtype approximated by receptor status. Breast J. 2014 Jul;20(4):358-63.   PMCID: 4472437
Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B. Trabectedin as a Single-Agent Treatment of Advanced Breast Cancer After Anthracycline and Taxane Treatment: A Multicenter, Randomized, Phase II Study Comparing 2 Administration Regimens. Clinical Breast Cancer. 2014 Dec;14(6):396-404.
Goldstein LJ, Miller BJ, Nicotera N, Pendleton D. Reducing the time from initial call to first appointment: the impact of patient access redesign and a nurse navigation program. J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S16-8.   PMCID: No NIH funds
Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R, Nccn. Breast Cancer Version 3.2014 Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2014 Apr;12(4):542-90.   PMCID: No NIH funds
Matro JM, Goldstein LJ. How Do I Follow Patients With Early Breast Cancer After Completing Adjuvant Therapy. Current treatment options in oncology. 2014 Mar;15(1):63-78.   PMCID: No NIH funds
Silverman D, Ruth K, Sigurdson ER, Egleston BL, Goldstein LJ, Wong YN, Boraas M, Bleicher RJ. Skin involvement and breast cancer: are T4b lesions of all sizes created equal?. Journal of the American College of Surgeons. 2014 Sep;219(3):534-44.   PMCID: Pmc4143438
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, Davidson N, Goldstein LJ, Miller KD, Sparano JA. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy Little Evidence of Improvement Over the Past 30 Years. Cancer. 2013 Mar;119(6):1140-8.   PMCID: PMC3593800
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R. Breast Cancer, Version 3.2013 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2013 Jul;11(7):753-61.   PMCID: No NIH funds
Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li TY, Swaby RF, Ma CM, Li JS, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ. Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer. International Journal of Radiation Oncology Biology Physics. 2012 Nov;84(4):888-93.   PMCID: PMC3419789
Freedman GM, Li TY, Polli LV, Anderson PR, Bleicher RJ, Sigurdson E, Swaby R, Dushkin H, Patchefsky A, Goldstein L. Lymphatic Space Invasion is Not an Independent Predictor of Outcomes in Early Stage Breast Cancer Treated by Breast-Conserving Surgery and Radiation. Breast Journal. 2012 Sep;18(5):415-9.
Li L, Li T, Cohen RJ, Anderson PR, Goldstein LJ, Bleicher RJ, Freedman GM. Identifying patients who may be candidates for a clinical trial of salvage accelerated partial breast irradiation after previous whole breast irradiation. Int J Breast Cancer. 2012 Jan;2012:937658.   PMCID: PMC3518959
Solin LJ, Gray R, Goldstein LJ, Recht A, Baehner FL, Shak S, Badve S, Perez EA, Shulman LN, Martino S, Davidson NE, Sledge GW, Sparano JA. Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Research and Treatment. 2012 Jul;134(2):683-92.   PMCID: PMC 3552372
Sparano JA, Goldstein LJ, Davidson NE, Sledge GW, Gray R. TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment. 2012 Jul;134(2):751-7.
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Lara JF, Thor AD, Dressler LG, Broadwater G, Bleiweiss IJ, Edgerton S, Cowan D, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Hayes DF, Canc Leukemia Grp B. p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905). Clinical Cancer Research. 2011 Aug;17(15):5170-8.   PMCID: PMC319770
Murphy C, Anderson PR, Li TY, Bleicher RJ, Sigurdson ER, Goldstein LJ, Swaby R, Denlinger C, Dushkin H, Nicolaou N, Freedman GM. IMPACT OF THE RADIATION BOOST ON OUTCOMES AFTER BREAST-CONSERVING SURGERY AND RADIATION. International Journal of Radiation Oncology Biology Physics. 2011 Sep;81(1):69-76.   PMCID: PMC2992091
Sparano JA, Goldstein LJ, Childs BH, Shak S, Brassard D, Badve S, Baehner FL, Bugarini R, Rowley S, Perez EA, Shulman LN, Martino S, Davidson NE, Kenny PA, Sledge GW, Gray R. Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer. Clinical Cancer Research. 2011 Nov;17(22):7194-203.   PMCID: PMC3570203
Abramowitz MC, Li TY, Morrow M, Anderson PR, Bleicher RJ, Goldstein LJ, Swaby R, Nicoloau N, Freedman GM. History of Smoking is Associated with Younger Age at Diagnosis of Breast Cancer. Breast Journal. 2010 Jul;16(4):344-9.   PMCID: not NIH funded
Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Smith ML, Som G, Topham NS, Ward JH, Winer EP, Wolff AC. Breast Cancer: Noninvasive and Special Situations. Journal of the National Comprehensive Cancer Network. 2010 Oct;8(10):1182-207.   PMCID: not NIH funded
Dotan E, Goldstein LJ. Optimizing chemotherapy regimens for patients with early-stage breast cancer. Clin Breast Cancer. 2010 Jul;10:E8-E15.   PMCID: no funding
Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. Journal of Clinical Oncology. 2008 May 20;26(15):2473-81.
Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008 Jan;6 Suppl 4:S1-S25; quiz S26-S27.
Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clinical Cancer Research. 2008 Jul;14(14):4484-90.
Goldstein LJ. Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer. 2008 Jan;:25-8.
Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep;26(25):4063-71.
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008 Sep;26(25):4092-9.
Borghaei H, Katherine Alpaugh R, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007 May;30(4):455-67.
Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys. 2007 Mar 20;68(2):347-53.
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine. 2007 Oct;357(15):1496-506.
O'Grady MA, Gitelson E, Swaby RF, Goldstein LJ, Sein E, Keeley P, Miller B, Li T, Weinstein A, Cohen SJ. Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the fox chase cancer center partners initiative. J Natl Compr Canc Netw. 2007 Oct;5(9):875-82.
Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Apr;295(14):1658-67.
Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group. Cancer Investigation. 2006 Nov;24(7):677-81.
Freedman GM, Anderson P, Li TY, Ross E, Swaby R, Goldstein L. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer. 2006 Dec;107(11):2552-8.
Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
Manne SL, Ostroff JS, Norton TR, Fox K, Goldstein L, Grana G. Cancer-related relationship communication in couples coping with early stage breast cancer. PSYCHO-ONCOLOGY. 2006 Mar;15(3):234-47.
Manne SL, Ostroff JS, Norton TR, Fox K, Grana G, Goldstein L. Cancer-specific self-efficacy and psychosocial and functional adaptation to early stage breast cancer. Ann Behav Med. 2006 Apr;31(2):145-54.
Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?. J Clin Oncol. 2006 Jun 20;24(18):2694-6.
Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. The oncologist. 2004 Jan;9 (6):606-16.
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clinical Cancer Research. 2004 Nov;10(21):7220-8.
Manne S, Ostroff J, Rini C, Fox K, Goldstein L, Grana G. The Interpersonal Process Model of Intimacy: The Role of Self-Disclosure, Partner Disclosure, and Partner Responsiveness in Interactions Between Breast Cancer Patients and Their Partners. Journal of Family Psychology. 2004 Jan;18(4):589-99.
Manne S, Ostroff J, Winkel G, Goldstein L, Fox K, Grana G. Posttraumatic growth after breast cancer: Patient, partner, and couple perspectives. Psychosomatic Medicine. 2004 May;66(3):442-54.
Sundermeyer ML, Goldstein LJ. American Society for Clinical Oncology 40th annual meeting, New Orleans, LA, 5-8 June 2004: breast cancer highlights. Breast Cancer Research. 2004 Jan;6(6):275-8.
Tedesco KL, Thor AD, Johnson DH, Shyr Y, Blum KA, Goldstein LJ, Gradishar WJ, Nicholson BP, Merkel DE, Murrey D, Edgerton S, Sledge GW. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. Journal of Clinical Oncology. 2004 Mar;22(6):1071-7.
Wallace SG, Goldstein LJ. Nonepithelial malignancies of the breast - The Chugh/Baker article reviewed. ONCOLOGY-NEW YORK. 2004 May;18(5):675-6.
Freedman GM, Anderson PR, Goldstein LJ, Hanlon AL, Cianfrocca ME, Millenson MM, von Mehren M, Torosian MH, Boraas MC, Nicolaou N, Patchefsky AS, Evers K. Routine mammography is associated with earlier stage disease and greater eligibility for breast conservation in breast carcinoma patients age 40 years and older. Cancer. 2003 Sep;98(5):918-25.
Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E, Schilsky RL, Wood WC, Muss HB, Norton L. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976-83.
Schulman KA, Stadtmauer EA, Reed SD, Glick HA, Goldstein LJ, Pines JM, Jackman JA, Suzuki S, Styler MJ, Crilley PA, Klumpp TR, Mangan KF, Glick JH. Economic analysis of conventional-dose chemotherapy compared with high- dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Bone Marrow Transplantation. 2003 Feb;31(3):205-10.
Traut D, Goldstein LJ. Adjuvant therapy: taxanes. Journal of the National Comprehensive Cancer Network. 2003 Jan;1(2):222-9.
Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul;21(13):2597-9.
Russin MP, Goldstein LJ. Chemotherapy in breast cancer. In: Torosian M, editor. Breast cancer : a guide to detection and multidisciplinary therapy. Totowa, N.J.: Humana Press; 2002. p. 145-59.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug;20(15):3317-27.
Cianfrocca M, Goldstein LJ. Operable breast cancer. Current treatment options in oncology. 2001 Apr;2(2):157-67.
Fowble B, Hanlon A, Freedman G, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Torosian M, Goldstein L. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys. 2000 Jul;47(4):883-94.
Stadtmauer EA, Goldstein LJ, Glick JH. High-dose chemotherapy plus hematopoietic stem-cell rescue for metastatic breast cancer - Reply. New England Journal of Medicine. 2000 Aug 10;343(6):440-1.
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. New England Journal of Medicine. 2000 Apr 13;342(15):1069-76.
Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. Journal of Clinical Oncology. 1999 Jun;17(6):1680-8.
Freedman G, Fowble B, Hanlon A, Nicolaou N, Fein D, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Patients with early stage invasive cancer with close or positive margins treated with conservative surgery and radiation have an increased risk of breast recurrence that is delayed by adjuvant systemic therapy. International Journal of Radiation Oncology Biology Physics. 1999 Jul 15;44(5):1005-15.
Dexter DW, Reddy RK, Geles KG, Bansal S, Myint MA, Rogakto A, Leighton JC, Goldstein LJ. Quantitative reverse transcriptase-polymerase chain reaction measured expression of MDR1 and MRP in primary breast carcinoma. Clinical Cancer Research. 1998 Jun;4(6):1533-42.
Fowble B, Hanlon AL, Patchefsky A, Freedman G, Hoffman JP, Sigurdson ER, Goldstein LJ. The presence of proliferative breast disease with atypia does not significantly influence outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. International Journal of Radiation Oncology Biology Physics. 1998 Aug;42(1):105-15.
Freedman GM, Fowble BL, Hanlon AL, Myint MA, Hoffman JP, Sigurdson ER, Eisenberg BL, Goldstein LJ, Fein DA. A close or positive margin after mastectomy is not an indication for chest wall irradiation except in women aged fifty or younger. International Journal of Radiation Oncology Biology Physics. 1998 Jun;41(3):599-605.
Freedman GM, Fowble BL, Hanlon AL, Fein DA, Hoffman JP, Sigurdson ER, Goldstein LJ. Postmastectomy radiation and adjuvant systemic therapy: outcomes in high-risk women with stage II-III breast cancer and assessment of clinical, pathologic, and treatment-related factors influencing local-regional control. Breast Journal. 1997 Nov;3(6):337-44.
Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: An eastern cooperative oncology group study. Journal of Clinical Oncology. 1997 May;15(5):1880-4.
Fowble B, Fein DA, Hanlon AL, Eisenberg BL, Hoffman JP, Sigurdson ER, Daly MB, Goldstein LJ. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. International Journal of Radiation Oncology Biology Physics. 1996 Jul;35(4):669-77.
Goldstein LJ. MDR1 gene expression in solid tumours. European Journal of Cancer. 1996 Jun;32A(6):1039-50.
Crilley P, Goldstein LJ. Peripheral-Blood Stem-Cell Transplant in Breast-Cancer. Seminars in Oncology. 1995 Jun;22(3):238-49.
Sledge GW, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskillstevens W. Eastern-Cooperative-Oncology-Group Studies of Paclitaxel and Doxorubicin in Advanced Breast-Cancer. Seminars in Oncology. 1995 Jun;22(3):105-8.
Kruh GD, Goldstein LJ. Doxorubicin and multidrug resistance. Current Opinion in Oncology. 1993 Jan;5(6):1029-34.
Lerman C, Daly M, Sands C, Balshem A, Lustbader E, Heggan T, Goldstein L, James J, Engstrom P. Mammography Adherence and Psychological Distress among Women at Risk for Breast-Cancer. Journal of the National Cancer Institute. 1993 Jul 07;85(13):1074-80.
Sauter ER, Eisenberg BL, Hoffman JP, Ottery FD, Boraas MC, Goldstein LJ, Solin LJ. Postmastectomy Morbidity after Combination Preoperative Irradiation and Chemotherapy for Locally Advanced Breast-Cancer. World Journal of Surgery. 1993 Mar;17(2):237-42.
Sauter ER, Eisenberg BL, Hoffman JP, Ottery FD, Boraas MC, Goldstein LJ, Solin LJ, Kinne DW. Postmastectomy morbidity after combination preoperative irradiation and chemotherapy for locally advanced breast cancer. World Journal of Surgery. 1993 Jan;17(2):237-42.
Goldstein LJ, Pastan I, Gottesman MM. Multidrug Resistance in Human Cancer. Critical Reviews in Oncology/Hematology. 1992 May;12(3):243-53.
Bookman MA, Goldstein LJ, Scher RM. Medical-Management of Early-Stage Breast-Cancer. Current Problems in Cancer. 1991 Jul;15(4):161-232.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

Lori Goldstein Sparkline Graph

Graph Interactions

Co-Authors:

Similar Investigators:


Keywords (MeSH):


Last updated on Friday, December 06, 2019